Role of Iron Deficiency in Heart Failure-Clinical and Treatment Approach: An Overview
- PMID: 36673114
- PMCID: PMC9857585
- DOI: 10.3390/diagnostics13020304
Role of Iron Deficiency in Heart Failure-Clinical and Treatment Approach: An Overview
Abstract
Background: The association of chronic heart failure (CHF) and iron deficiency (ID) with or without anemia is frequently encountered in current medical practice and has a negative prognostic impact, worsening patients' exercise capacity and increasing hospitalization costs. Moreover, anemia is common in patients with chronic kidney disease (CKD) and CHF, an association known as cardio-renal anemia syndrome (CRAS) possessing a significantly increased risk of death.
Aim: This review aims to provide an illustrative survey on the impact of ID in CHF patients-based on physiopathological traits, clinical features, and the correlation between functional and absolute ID with CHF-and the benefit of iron supplementation in CHF.
Method: We selected the most recent publications with important scientific content covering the association of CHF and ID with or without anemia.
Discussions: An intricate physiopathological interplay is described in these patients-decrease in erythropoietin levels, activation of the renin-angiotensin-aldosterone system, systemic inflammation, and increases in hepcidin levels. These mechanisms amplify anemia, CHF, and CKD severity and worsen patients' outcomes.
Conclusions: Anemia is frequently encountered in CHF and represents a negative prognostic factor. Data from randomized controlled trials have underlined the administration of intravenous iron therapy (ferric carboxymaltose) as the only viable treatment option, with beneficial effects on quality of life and exercise capacity in patients with ID and systolic heart failure.
Keywords: chronic heart failure; hemoglobin; iron deficiency anemia.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Iron Deficiency and its Relationship with Chronic Heart Failure- A Review.Cardiovasc Hematol Agents Med Chem. 2024 Sep 25. doi: 10.2174/0118715257313681240913112017. Online ahead of print. Cardiovasc Hematol Agents Med Chem. 2024. PMID: 39323346
-
Anemia, chronic renal disease and congestive heart failure--the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists.Int Urol Nephrol. 2006;38(2):295-310. doi: 10.1007/s11255-006-0064-8. Int Urol Nephrol. 2006. PMID: 16868702 Review.
-
The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome.Heart Fail Rev. 2011 Nov;16(6):609-14. doi: 10.1007/s10741-010-9194-2. Heart Fail Rev. 2011. PMID: 20865450 Review.
-
Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome.Nat Clin Pract Cardiovasc Med. 2005 Feb;2(2):95-100. doi: 10.1038/ncpcardio0094. Nat Clin Pract Cardiovasc Med. 2005. PMID: 16265380 Review.
-
The interaction between heart failure and other heart diseases, renal failure, and anemia.Semin Nephrol. 2006 Jul;26(4):296-306. doi: 10.1016/j.semnephrol.2006.05.006. Semin Nephrol. 2006. PMID: 16949468 Review.
Cited by
-
Outcomes of Early Versus Delayed Anemia Treatment in Nondialysis-Dependent CKD.Kidney Int Rep. 2024 Apr 15;9(7):2056-2066. doi: 10.1016/j.ekir.2024.04.030. eCollection 2024 Jul. Kidney Int Rep. 2024. PMID: 39081766 Free PMC article.
-
Challenges in Diagnosis and Therapeutic Approach of Acute on Chronic Liver Failure-A Review of Current Evidence.Biomedicines. 2023 Jun 26;11(7):1840. doi: 10.3390/biomedicines11071840. Biomedicines. 2023. PMID: 37509478 Free PMC article. Review.
-
Associated factors in pediatric patients admitted with severe iron-deficiency anemia in the last seven years - the experience of a single pediatric unit.Rom J Morphol Embryol. 2023 Jul-Sep;64(3):419-426. doi: 10.47162/RJME.64.3.13. Rom J Morphol Embryol. 2023. PMID: 37867359 Free PMC article.
-
Managing Anemia: Point of Convergence for Heart Failure and Chronic Kidney Disease?Life (Basel). 2023 Jun 1;13(6):1311. doi: 10.3390/life13061311. Life (Basel). 2023. PMID: 37374094 Free PMC article. Review.
-
The Efficacy and Safety of Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.Diseases. 2024 Dec 22;12(12):339. doi: 10.3390/diseases12120339. Diseases. 2024. PMID: 39727669 Free PMC article. Review.
References
-
- Lippi G., Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med. J. 2020;5:15. doi: 10.21037/amj.2020.03.03. - DOI
Publication types
LinkOut - more resources
Full Text Sources